Previous studies have shown the promising benefit of anti-PD-1 therapy in many tumor types (13–15) and a good response in patients with ampullary or cholangiocarcinoma harboring the MSI phenotype (7). This evidence concerns the gene PDCD1 and cholangiocarcinoma.